Genmab A/S

GMAB · Nasdaq Copenhagen · Healthcare

2,257.00DKK −2.4%last day

Price as of 2 October 2026

The price over the past year, with dividends: +23.2%

Performance

1 month

+2.7%

1 year

+23.2%

3 years, per year

−3.7%

5 years, per year

−4.2%

Largest fall, 3 years

−64.5%

Below the peak now

−31.5%

Volatility, 1 year

33.8%

Return with dividends reinvested.

Key figures

P/E

26.6

P/B

3.5

Dividend yield

0.0%

Return on equity

+13.2%

Net margin

+19.0%

Market value

21.0 bn USD

Quality, value and trend

Where Genmab stands against every Nordic stock today. 100 is best.

Quality80

Profitability and a sound balance sheet over time. Better than 80% of Nordic stocks.

Value25

The price measured against earnings, assets and cash flow. Better than 25% of Nordic stocks.

Trend89

The price development over the past year. Better than 89% of Nordic stocks.

Combined79

Quality, value and trend together. Better than 79% of Nordic stocks.

About Genmab

Genmab A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 3,100 employees.

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis